Verastem, Inc. (VSTM) News

Verastem, Inc. (VSTM): $3.00

0.08 (+2.74%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add VSTM to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#107 of 331

in industry

Filter VSTM News Items

VSTM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VSTM News Highlights

  • For VSTM, its 30 day story count is now at 3.
  • Over the past 5 days, the trend for VSTM's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • RAMP and SAFE are the most mentioned tickers in articles about VSTM.

Latest VSTM News From Around the Web

Below are the latest news stories about VERASTEM INC that investors may wish to consider to help them evaluate VSTM as an investment opportunity.

Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics

BOSTON, December 18, 2023--Verastem Oncology (Nasdaq: VSTM) (the "Company"), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a potential best-in-class KRAS G12D oral inhibitor as the lead program of its discovery and development collaboration with GenFleet Therapeutics ("GenFleet").

Yahoo | December 18, 2023

3 Off-the-Beaten-Path Stocks Poised for Substantial Growth

As horror film fans know, there’s safety in numbers but robust profitability may be more closer to the domain of uncommon stocks to buy for growth.

Josh Enomoto on InvestorPlace | December 13, 2023

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

BOSTON, December 13, 2023--Verastem Oncology (Nasdaq: VSTM) (the "Company"), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that it has initiated its international confirmatory Phase 3 RAMP 301 trial (GOG-3097; ENGOT-ov81/NCRI), evaluating the combination of avutometinib and defactinib versus standard chemotherapy or hormonal therapy for the treatment of recurrent low-grade serous ovarian cancer (LGSOC).

Yahoo | December 13, 2023

Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential

If the first rule in the film “Fight Club” is to not talk about fight club, then the same rule applies to penny stocks with potential: you do not talk about these penny stocks with upside.

Josh Enomoto on InvestorPlace | December 3, 2023

3 Penny Stocks to Buy to Turn $1 into $100: November 2023

Are you looking for outsized gains for your portfolio.

Gabriel Osorio-Mazzilli on InvestorPlace | November 22, 2023

All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy

Verastem (VSTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | November 22, 2023

New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach

BOSTON, November 13, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the launch of the new healthcare professional component of Let’s Talk About LGSOC, designed to support clinicians in the diagnosis and management of low-grade serous ovarian cancer (LGSOC). Let’s Talk About LGSOC provides detailed information about the unique clinical, histopathological, and molecular features of LGSOC, current N

Yahoo | November 13, 2023

Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

BOSTON, November 08, 2023--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the third quarter ending September 30, 2023 and highlighted recent progress.

Yahoo | November 8, 2023

First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer

BOSTON, November 07, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced results of the first-ever LGSOC Patient Impact Survey that reveal the particular challenges with diagnosis, disease management and mental, physical, and emotional well-being experienced by people living with low-grade serous ovarian cancer (LGSOC)*.1 This multi-national, online survey was conducted by The Harris Poll on behalf of

Yahoo | November 7, 2023

Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population

BOSTON, November 06, 2023--Verastem Oncology (Nasdaq: VSTM) (the "Company"), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today results of the efficacy and safety of avutometinib and defactinib in recurrent low-grade serous ovarian cancer (LGSOC) following prior systemic therapy. The results of this planned subgroup analysis of Part A of the Phase 2 RAMP 201 (ENGOT-ov60/GOG-3052) trial were presented as a late-breaking abstract in an oral p

Yahoo | November 6, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!